Trial intelligence / Profile preview

PF-08634404 plus chemotherapy for first-line extensive-stage small cell lung cancer

2025-523522-41-00Phase 3Authorised

Sponsor: Pfizer
Start: Apr 2026
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Countries: 11

Overview

Phase 3 trial of PF-08634404 in small cell lung cancer (SCLC) (2 arms), sponsored by Pfizer. Primary endpoints: Confirmed objective response rate, Adverse events and 1 more. Planned start Apr 2026; status: authorised.

Drugs

PF-08634404

Conditions

small cell lung cancer (SCLC)

Beyond the preview

Go deeper on 2025-523522-41-00.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2025-523522-41-00.